Senzime is a Swedish medical device company that develops, manufactures, and markets CE- and FDA-cleared patient monitoring systems. Senzime’s employees worldwide are committed to the vision of a world free of postoperative complications. The company markets an innovative portfolio of solutions, including TetraGraph® and ExSpiron® 2Xi for monitoring of neuromuscular and respiratory functions, typically under and after surgery. The goal is to help eliminate postoperative complications for more than 100 million patients worldwide.\n\nBacked by strong institutional long-term owners, our shares are listed on Nasdaq Stockholm Main Market (SEZI) and cross traded in the US on OTCQX (SNZZF).